Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEMAFLOT
2024-514078-29-00Phase 2Completed
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bemarituzumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Institut Cancérologique de l'Ouest. Primary endpoint: Complete pathological response by Becker tumor regression grading. Started May 2025; status: completed.
02
Drugs
bemarituzumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2024-514078-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514078-29-00.